Aladdin Healthcare Technologies SE gained approval by the Dementias Platform UK (DPUK) for accessing important biobanks containing a huge amount of medical data for dementia research. This data sets the stage for significant potential breakthroughs for new biomarkers for a novel affordable non-invasive global test that would create a new gold standard for Alzheimer's testing and place Aladdin at the forefront of new generation diagnostic leaders. Early this year, Aladdin applied for data access of important bio-databanks of the Dementias Platform UK. DPUK is a public-private partnership funded and led by the Medical Research Council (MRC) which aims to improve the early detection, treatment and prevention of dementia. The organisation is directed by Professor John Gallacher at the University of Oxford and involves several renowned academic and industry partners, such as the University of Cambridge, the King's College in London and GlaxoSmithKline. The DPUK Data Portal provides researchers and companies with about 40 of UK's existing population studies and with medical records of more than three million participants. Researchers can identify which data of cohort studies are relevant to them and apply for gaining access to the data. After approval, the multimodal data can be analysed and used for further healthcare findings. Aladdin has recently gained approval for accessing the following cohort studies of DPUK, which are some of the richest data cohorts for dementia research: Whitehall II, BRACE, ELSA and Generation Scotland. This gives the Company the chance to improve its Artificial Intelligence (AI) assisted discovery process for early diagnosis of age-related neurodegenerative diseases. The new data can add significant new information to Aladdin's proprietary Knowledge Graph and lead to more discoveries for new biomarkers. Gaining access to these valuable biobanks is a further evidence of Aladdin's ability to work with renowned international research partners. This represents the first step towards a bigger project of closing an official partnership and becoming a consortium member of the DPUK.